CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.
Second quarter CAPLYTA total prescriptions (TRx) increased 22% versus the previous…
